Erratum: Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: A randomized, placebo-controlled trial (Prostate Cancer and Prostatic Diseases (2007) vol. 10 (155-159) 10.1038/sj.pcan.4500925));Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: A randomized, placebo-controlled trial

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 2, 2007, Pages 155-159

  Resnick, M I ^a   Roehrborn, C G ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FLOW RATE; GASTROESOPHAGEAL REFLUX; GROUPS BY AGE; HEADACHE; HEART PALPITATION; HUMAN; INFORMED CONSENT; INSOMNIA; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TRANSRECTAL ULTRASONOGRAPHY; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; UROFLOWMETRY; VASODILATATION; XEROSTOMIA;

EID: 34249977256     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500981     Document Type: Erratum

References (18)

1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-547.
2. Chapple CR, Aubry ML, James S, Greengrass PM, Burnstock G, Turner-Warwick RT et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol 1989; 63: 487-496.
3. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alphal-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13.
4. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol 1997; 31: 190-198.
5. The Italian Alfuzosin Co-Operative Group. Safety, efficacy and impact on patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. Eur Urol 2000; 37: 680-686.
6. Lukacs B, Grange JC, Comet D. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology 2000; 55: 540-546.
7. Sanchez-Chapado M, Guil M, Alfaro V, Badiella L, Fernandez-Hernando N. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3095 Spanish patients evaluated during general practice. Eur Urol 2000; 37: 421-427.
8. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257-261.
9. Marks LS, Roehrborn CG, Gittelman M, Kim D, Forrest J, Jacobs S. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology 2003; 62: 888-893.
10. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewite RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557; discussion 1564.
11. Barry M, Batista J, Donovan J et al. Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. In: Chatelain C, Denis L, Foo K, Khoury S, McConnell J (eds). Benign Prostatic Hyperplasia. Health Publication: United Kingdom, 2001, pp 203-220.
12. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care 1995; 33: AS145-AS155.
13. Van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000; 37: 306-313.
14. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 2001; 58: 953-959.
15. Nordling J. Efficacy and safety of two doses (10 and 15mg) of alfuzosin or tamsulosin (0.4mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005; 95: 1006-1012.
16. McKeage K, Plosker GL. Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633-653.
17. Roehrborn CG. Alfuzosin 10mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: Results of a 2-year placebo-controlled study. BJU Int 2006; 97: 734-741.
18. Van Kerrebroeck P, Jardin A, van Cangh P, Laval KU. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-label extension study. Eur Urol 2002; 41: 54-60; discussion 60-61.